2026 NPPES data Orthopaedic Surgery Physician NPI 1548288194 M.D.
Verify on CMS →

JAMES KAYVANFAR, M.D.

Orthopaedic Surgery Physician in NEWHALL, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
613
Medicare Part D claims · 134 beneficiaries · Orthopaedic Surgery Physician avg: 324
Generic prescribing
48%
generic claims · 52% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
100/100
▲ 17 pts above national avg 83.1 · [object Object]
Industry payments
$719.9
30 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

JAMES KAYVANFAR, M.D. reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 613 Medicare Part D claims in 2023.

100/100
MIPS score · +17 vs avg
613
Part D claims, 2023
48%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

JAMES KAYVANFAR, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

100 Top 7% higher than 93% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

JAMES KAYVANFAR, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about JAMES KAYVANFAR, M.D.?

High performer (top quartile)

NPI registry status

Active

Issued 07/18/2006

NPI 1548288194

Primary specialty

Orthopaedic Surgery Physician

Mid-sized

25,781 US NPIs in this specialty

Medicare Part D claims

613 89% vs specialty avg

2023 prescription claims

Specialty avg: 324

MIPS final score

100/100 16.900000000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in California

How Orthopaedic Surgery Physician compares to other specialties among California providers

California providers

Orthopaedic Surgery Physician share within California

1. Orthopaedic Surgery Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Orthopaedic Surgery Physician share within California

Medicare quality performance — MIPS

JAMES KAYVANFAR, M.D.'s 2023 MIPS final score plotted against the Orthopaedic Surgery Physician national average

High performer (top quartile)
MIPS Final Score
100/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Orthopaedic Surgery Physician) — 100/100 vs national avg 83.1

0%100%National avg83%99%
MIPS final score (Orthopaedic Surgery Physician) — 100/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

JAMES KAYVANFAR, M.D. appears in the CMS NPPES registry as a Orthopaedic Surgery Physician provider holding M.D. credentials at 24318 WALNUT ST, NEWHALL, CA, 91321, with a listed phone of (661) 222-9466. NPI 1548288194 was issued on 07/18/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KAYVANFAR most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 613 prescription claims written by this provider, covering 134 Medicare beneficiaries and totaling roughly $949K in drug spend, split 52% brand-name and 48% generic by claim count, with an opioid prescribing rate of 2.4%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100), compared with the national average of 83.1.

Orthopaedic Surgery Physician is a mid-sized specialty nationwide, with 25,781 enrolled providers across 56 states and an average of 324 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

24318 WALNUT ST
NEWHALL, CA 91321

Provider Details

NPI 1548288194
Specialty Orthopaedic Surgery Physician
Credentials M.D.
Gender Male
NPI Issued 07/18/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

100
Final Score
Avg: 83.1
100
Quality

Reporting: Individual

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for JAMES KAYVANFAR, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$720

Largest payer

Medtronic, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to JAMES KAYVANFAR, M.D.. To verify JAMES KAYVANFAR, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

JAMES KAYVANFAR, M.D. — brand share 52.0%
Specialty average (est.)

52% brand-name claims vs 48% generic, on 613 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

613
Total Claims
$949K
Total Drug Cost
134
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
910
Total Day Supply
25,894
Brand vs Generic
52% brand / 48% generic
Brand Drug Cost
$942K
Generic Drug Cost
$7K
Opioid Claims
15 (2.4% rate)
Antibiotic Claims
25

Patient Demographics

Average Patient Age
77.9 years
Avg HCC Risk Score
1.56
Gender Split
69% female / 31% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What JAMES KAYVANFAR, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Tymlos
Abaloparatide
176
Pregabalin
82
Forteo
Teriparatide
81
Alendronate Sodium
70
Celecoxib
49
Prolia
Denosumab
42
Cephalexin
14
Tramadol Hcl
13
Teriparatide
11
Ultra-Fine Mini Pen Needle
"Pen Needle
N/A

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Orthopaedic Surgery Physician Overview

How JAMES KAYVANFAR, M.D. fits within the Orthopaedic Surgery Physician landscape nationally.

25,781
Orthopaedic Surgery Physician Providers in US
56
States with Orthopaedic Surgery Physician
324
Avg Claims per Provider

JAMES KAYVANFAR, M.D.'s 613 claims are above the specialty average of 324.

Nearby Orthopaedic Surgery Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as KAYVANFAR.

Compare Orthopaedic Surgery Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is JAMES KAYVANFAR, M.D.'s specialty?
JAMES KAYVANFAR, M.D. specializes in Orthopaedic Surgery Physician and practices in NEWHALL, California. Credentials: M.D..
How much does JAMES KAYVANFAR, M.D. prescribe under Medicare Part D?
In 2023, JAMES KAYVANFAR, M.D. wrote 613 Medicare Part D claims totaling $949K in drug costs for 134 beneficiaries.
What is JAMES KAYVANFAR, M.D.'s Medicare quality score?
JAMES KAYVANFAR, M.D. has a CMS MIPS Final Score of 100/100 (Quality: 100). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is JAMES KAYVANFAR, M.D. located?
JAMES KAYVANFAR, M.D. is located at 24318 WALNUT ST, NEWHALL, CA, 91321. Phone: (661) 222-9466.
What is JAMES KAYVANFAR, M.D.'s NPI number?
JAMES KAYVANFAR, M.D.'s National Provider Identifier (NPI) is 1548288194, issued on 07/18/2006.
Does JAMES KAYVANFAR, M.D. prescribe more brand-name or generic drugs?
JAMES KAYVANFAR, M.D.'s prescribing is 52% brand-name and 48% generic drugs by claim count, with $942K in brand drug costs.
Does JAMES KAYVANFAR, M.D. prescribe opioids?
Yes, JAMES KAYVANFAR, M.D. had 15 opioid claims in 2023 with an opioid prescribing rate of 2.4%.
How many Orthopaedic Surgery Physician providers are there in the US?
There are 25,781 Orthopaedic Surgery Physician providers across 56 states in the US. The average Orthopaedic Surgery Physician provider writes 324 Medicare Part D claims per year.
What drugs does JAMES KAYVANFAR, M.D. prescribe most often?
Based on 2023 Medicare Part D data, JAMES KAYVANFAR, M.D.'s most frequently prescribed drugs include Tymlos, Pregabalin, Forteo. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does JAMES KAYVANFAR, M.D. accept Medicare?
JAMES KAYVANFAR, M.D. appears in CMS Medicare data with 613 Part D claims and 134 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify JAMES KAYVANFAR, M.D.'s credentials?
JAMES KAYVANFAR, M.D.'s NPI is 1548288194 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology